ORBIMED ADVISORS LLC
Q1 2024 13F-HR Holdings
Net value change ($000)
+452,716
(9.0%)
New positions
20
Sold out positions
17
Turnover %
18.0%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q4 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| JANX | 125,374 | 352.2% |
| EWTX | 114,631 | 71.9% |
| LLY | 67,689 | 31.8% |
| MRK | 58,630 | 51.0% |
| ALPINE IMMUNE SCIENCES, INC. | 57,933 | 119.9% |
| AVBP | 54,068 | NEW |
| CYTK | 47,864 | NEW |
| SPRY | 43,802 | 86.5% |
| GERN | 41,526 | 4059.2% |
| QTTB | 38,391 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| RayzeBio, Inc. | -147,045 | -100.0% |
| Gracell Biotechnologies Inc. | -93,460 | -100.0% |
| UTHR | -84,900 | -100.0% |
| Theseus Pharmaceuticals, Inc. | -71,740 | -100.0% |
| R1 RCM Inc. /DE | -50,770 | -100.0% |
| HUM | -50,313 | -100.0% |
| BMRN | -39,851 | -26.3% |
| IOVA | -38,272 | -100.0% |
| SpringWorks Therapeutics, Inc. | -33,472 | -28.5% |
| Fusion Pharmaceuticals Inc. | -30,010 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
12,910
(0.2% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|